Contact Us Donate Now
Home / Media

Media

OCCPR Leading the War Against Cancer in the Next Battlefield: Proteomics and Protegenomics

Jun 25, 2022

OCCPR Leading the War Against Cancer in the Next Battlefield: Proteomics and Protegenomics

The Office of Cancer Clinical Proteomics Research (OCCPR) is the NCI's workhorse in proteomics and proteogenomics research.
The Next Horizon in Precision Oncology

Jun 22, 2022

The Next Horizon in Precision Oncology

The Next Horizon in Precision Oncology: Proteogenomics for cancer diagnosis and treatment. This Perspective which was published in Cell 2021, discussed the latest advances in genetic and molecular cancer diagnosis and opportunities for new treatment modalities.
In the Breast Cancer month: Breast Cancer Awareness and Education Lecture from Dr. Seza Gulec

Oct 18, 2021

In the Breast Cancer month: Breast Cancer Awareness and Education Lecture from Dr. Seza Gulec

In Breast Cancer Awareness month, our President and CEO, Dr. Seza Gulec, will be conducting a lecture to the community of Bay Harbor Islands as part of the Health Education Lecture Series. Please join us in the October Health Educational Lecture via Zoom.

May 5, 2020

How to Think About Your Cancer Care in the Time of COVID-19

Getting the news that you have cancer is overwhelming and frightening. The COVID-19 crisis adds another layer of anxiety. But know this: you can protect yourself from COVID-19 without compromising your cancer treatment.

May 5, 2020

NCI Proteomics Data Commons

The PDC was developed to advance understanding of how proteins help to shape the risk, diagnosis, development, progression, and treatment of cancer.

May 5, 2020

NCI Office of Cancer Proteomics Research

NCI’s Office of Cancer Clinical Proteomics Research (OCCPR)

Apr 27, 2020

Cancer and COVID-19 — potentially deleterious effects of delaying radiotherapy

Radiotherapy can be safely delivered during the coronavirus disease 2019 (COVID-19) pandemic

Apr 28, 2019

Molecular Test Promising for Mutations in Thyroid Nodules

ThyroSeq v3 Genomic Classifier informative for DNA, RNA in sample with indeterminate FNA

Apr 28, 2019

Added Convenience of Classifying Nodules With ThyroSeq Test?

Findings from a study of the ThyroSeq Version 3 Genomic Classifier
Performance of ThyroSeq Test in Cytology Smears

Apr 28, 2019

Performance of ThyroSeq Test in Cytology Smears

Data Presented at the 2019 American Association of Clinical Endocrinologists Annual Meeting Demonstrate Performance of ThyroSeq Test in Cytology Smears

Apr 26, 2019

New Data on Diagnostic and Therapeutic Applications of ThyroSeq® Genomic Classifier Presented at the 2019 American Association of Clinical Endocrinologists Annual Meeting

Data from three studies demonstrating new diagnostic and therapeutic utility of ThyroSeq® Genomic Classifier

Jan 14, 2019

Validating a Molecular Thyroid Test for Avoiding Diagnostic Surgery

The study demonstrated that utilizing ThyroSeq testing for patients with indeterminate thyroid nodules may allow up to 82% of patients with histologically benign nodules to avoid diagnostic surgery.
Defining cancer oncobiology based on genomic and epigenomic expressions

Oct 15, 2018

Defining cancer oncobiology based on genomic and epigenomic expressions

We have entered in a personalized medicine paradigm with molecular theranostics. We are defining cancer oncobiology based on genomic and epigenomic expressions
The 2018 Nobel Prize in Physiology or Medicine jointly to James P. Allison and Tasuku Honjo

May 5, 2018

The 2018 Nobel Prize in Physiology or Medicine jointly to James P. Allison and Tasuku Honjo

The 2018 Nobel Prize in Physiology or Medicine jointly to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation.

Oct 23, 2017

ThyroSeq Announces Results of Large Multi-Center Study Validating New ThyroSeq V3 Test at the American Thyroid Association Meeting in Victoria, BC, Canada